Condition: Non-Small Cell Lung Cancer · Sponsor: Summit Therapeutics
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
This description comes directly from the study's public registry record.
Summit Clinical Trial Information · 1-833-256-0522 · medicalinformation@smmttx.com
Always discuss trial participation with your own doctor first.
| Banner University Medical Center | Phoenix, Arizona, United States | Recruiting |
| TMC Healthcare | Tucson, Arizona, United States | Recruiting |
| Genesis Cancer and Blood Institute | Hot Springs, Arkansas, United States | Recruiting |
| University of Arkansas | Little Rock, Arkansas, United States | Recruiting |
| LA Cancer Network | Anaheim, California, United States | Recruiting |
| The Oncology Institute of Hope & Innovation | Cerritos, California, United States | Recruiting |
| University of Southern California (USC) | Los Angeles, California, United States | Recruiting |
| Cedar Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Sutter Institute for Medical Research | Sacramento, California, United States | Recruiting |
| UC Davis Medical Center | Sacramento, California, United States | Recruiting |
| University of California Los Angeles (UCLA) | Santa Monica, California, United States | Recruiting |
+ 241 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05899608